Early Coronary Atherosclerosis in Women With Previous Preeclampsia

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Background: Women with previous preeclampsia have an increased risk of coronary artery disease later in life. Objectives: This study aimed to determine the prevalence of coronary atherosclerosis in younger women with previous preeclampsia in comparison with women from the general population. Methods: Women aged 40-55 years with previous preeclampsia were matched 1:1 on age and parity with women from the general population. Participants completed an extensive questionnaire, a clinical examination, and a coronary computed tomography angiography (CTA). The main study outcome was the prevalence of any coronary atherosclerosis on coronary CTA or a calcium score >0 in case of a nondiagnostic coronary CTA. Results: A total of 1,417 women, with a mean age of 47 years, were included (708 women with previous preeclampsia and 709 control subjects from the general population). Women with previous preeclampsia were more likely to have hypertension (284 [40.1%] vs 162 [22.8%]; P < 0.001), dyslipidemia (338 [47.7%] vs 296 [41.7%]; P = 0.023), diabetes mellitus (24 [3.4%] vs 8 [1.1%]; P = 0.004), and high body mass index (27.3 ± 5.7 kg/m2 vs 25.0 ± 4.2 kg/m2; P < 0.001). Cardiac computed tomography was performed in all women. The prevalence of any coronary atherosclerosis was higher in the preeclampsia group (193 [27.4%] vs 141 [20.0%]; P = 0.001) with an OR: 1.41 (95% CI: 1.08-1.85; P = 0.012) after adjustment for age, dyslipidemia, diabetes mellitus, smoking, body mass index, menopause, and parity. Conclusions: Younger women with previous preeclampsia had a slightly higher prevalence of coronary atherosclerosis compared with age- and parity-matched women from the general population. Preeclampsia remained an independent risk factor after adjustment for traditional cardiovascular risk factors. (The CoPenHagen PREeClampsia and cardIOvascUlar diSease study [CPH-PRECIOUS]; NCT03949829)

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind79
Udgave nummer23
Sider (fra-til)2310-2321
Antal sider12
ISSN0735-1097
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The CPH-PRECIOUS study received funding from The Danish Heart Foundation, Skibsreder Per Henriksen, R og Hustrus Fond, Kong Christian den Tiendes Fond, Brødrene Hartmanns Fond, Hans og Nora Buchards Fond, Arvid Nilssons Fond, Anita og Tage Therkelsens Fond, Fonden til Lægevidenskabens Fremme, Aase og Ejnar Danielsens Fond, Hjertecentrets Forskningsudvalg (Rigshospitalet), Direktør Kurt Bønnelycke og Hustru Fru Grethe Bønnelyckes Fond, Lægeforeningens Forskningsfond, Torben and Alice Frimodt Fond, and Henry og Astrid Møllers Fond. The CGPS was funded by AP Møller og hustru Chastine McKinney Møllers Fond, Research Council of Rigshopitalet, The University of Copenhagen, and The Danish Heart Foundation. The funders had no roles in the study. All foundations are Danish. Dr Damm has participated in clinical studies on the use of insulin in pregnant women with pre-existing diabetes in collaboration with Novo Nordisk; no personal honorarium is involved. Dr Kofoed has received research grants from AP Møller og hustru Chastine McKinney Møllers Fond, The John and Birthe Meyer Foundation, Research Council of Rigshopitalet, The University of Copenhagen, The Danish Heart Foundation, The Lundbeck Foundation, The Danish Agency for Science, Technology and Innovation by The Danish Council for Strategic Research, and Novo Nordisk Foundation; and has served on the Speakers Bureau of Canon Medical Systems. After initiation of this work, Dr Ersbøll has been employed by Novo Nordisk A/S; Novo Nordisk A/S is not involved in this project. Dr Sigvardsen has received consulting fees from Novo Nordisk A/S outside of the submitted work. Dr Gustafsson has received honoraria for serving as an advisor from Bayer, Abbott, Boehringer Ingelheim, Pfizer, Alnylam, Ionis, Pharmacosmos, and Amgen; and has received speakers fees from Orion Pharma and AstraZeneca, all not relevant to the study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2022 American College of Cardiology Foundation

ID: 310436337